GSK
3 years ago ⋅ English ⋅ 11 min read
Newsroom
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

For media and investors onlyIssued: London, UK and San Francisco, US- 600,000 additional doses to be supplied to the US Government for distribution in Q1 2022, enabling further access t... Read More
GSK
3 years ago ⋅ English ⋅ 9 min read
Newsroom
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

For media and investors only- Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company

New world-leader in Consumer Healthcare on track to list in 2022For media and investors onlyGlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Sir Dave Lewis has been appointed as... Read More
GSK
3 years ago ⋅ English ⋅ 9 min read
Newsroom
Xevudy (sotrovimab) granted marketing authorisation by the European Commission for the early treatment of COVID-19

For media and investors onlyIssued: London UK and San Francisco, USGlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commis... Read More
GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK and Sanofi announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of phase III trial per independent Monitoring Board recommendation

For media and investors only- Positive booster data show that neutralising antibodies increased across all primary vaccines received (mRNA or adenovirus) in a 9- to 43-fold range and fo... Read More
GSK
3 years ago ⋅ English ⋅ 12 min read
Newsroom
New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment

For media and investors only- DREAMM-9 phase I initial results demonstrate overall response rates (ORR) of 100% in three dosing cohorts and 83% in two dosing cohorts in newly diagnosed... Read More